Frequency of triple-positive breast cancer, according to pathomorphological laboratory

被引：0
|
作者：
Urezkova, M. [1 ]
Artemyeva, A. [1 ]
Semiglazova, T. [1 ]
Kudaibergenova, A. [1 ]
机构：
[1] NN Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia
来源：
VIRCHOWS ARCHIV | 2020年 / 477卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-02-05
引用
收藏
页码：S231 / S232
页数：2
相关论文
共 50 条
  • [21] Histopathological Patterns and Outcomes of Triple-Positive Versus Triple-Negative Breast Cancer: A Retrospective Study at a Tertiary Cancer Center
    Kadi, Mai S.
    Alhebshi, Alhasan H.
    Shabkah, Alaa A.
    Alzahrani, Walaa A.
    Enani, Ghada N.
    Samkari, Ali A.
    Iskanderani, Omar
    Saleem, Abdulaziz M.
    Farsi, Ali H.
    Trabulsi, Nora H.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [22] Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes
    Xie, Jie
    Yang, Zhihui
    Li, Zhuolin
    Zhang, Tianyu
    Chen, Huan
    Chen, Xueru
    Dai, Zehua
    Chen, Tao
    Hou, Jing
    CANCER CELL INTERNATIONAL, 2025, 25 (01)
  • [23] A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer
    Huo, Shiwen
    Xue, Jinqi
    Wang, Shuo
    Shan, Huilian
    Chen, Guanglei
    Niu, Nan
    Wang, Yimin
    Qiu, Fang
    Zhao, Yi
    Xing, Fei
    Zheng, Xinyu
    Tu, Wei
    Li, Ke
    Zhao, Hai
    Tang, Meiyue
    Xu, Qianshi
    Liu, Chao
    Zhao, Yafei
    Jiang, Xiaofan
    Pang, Zheng
    Zhang, Keliang
    Zhang, Dianlong
    Chen, Zhe-Sheng
    Liu, Caigang
    MEDCOMM, 2024, 5 (03):
  • [24] Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data
    You, Sun Hyong
    Chae, Bytmg Joo
    Eom, Yong Hwa
    Yoo, Tae-Kyung
    Kim, Yong-seok
    Kim, Jeong Soo
    Park, Woo-Chan
    JOURNAL OF BREAST CANCER, 2018, 21 (04) : 415 - +
  • [25] Triple-Positive Breast Carcinoma Histopathologic Features and Response to Neoadjuvant Chemotherapy
    Zeng, Jennifer
    Edelweiss, Marcia
    Ross, Dara S.
    Xu, Bin
    Moo, Tracy-Ann
    Brogi, Edi
    D'Alfonso, Timothy M.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (06) : 728 - 735
  • [26] Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial.
    Xue, Jinqi
    Niu, Nan
    Wang, Shuo
    Chen, Guanglei
    Qiu, Fang
    Zhao, Yi
    Xing, Fei
    Zheng, Xinyu
    Tu, Wei
    Li, Ke
    Zhao, Hai
    Tang, Meiyue
    Xu, Qianshi
    Liu, Chao
    Zhao, Yafei
    Jiang, Xiaofan
    Huo, Shiwen
    Pang, Zheng
    Zhang, Dianlong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Clinicopathological Features and Metastatic Pattern of Triple-positive Breast Cancer Among Female Patients at a Tertiary Care Hospital
    Alzahrani, Walaa
    Althoubaity, Fatma
    Alsobhi, Dur
    Mohamed, Yasmina
    AlMutairi, Amani
    Sindi, Dalia
    Alharbi, Rasha
    Zaidi, Nisar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (12)
  • [28] Adjuvant trastuzumab for triple-positive breast cancer with chronic renal failure: A case report and review of literature
    En, Wen
    Long, Yuming
    MEDICINE, 2024, 103 (01) : E36278
  • [29] Humanized mouse models of triple-negative and triple-positive breast cancer for preclinical validation of novel immuno-oncology therapies
    Kahkonen, T. E.
    Suominen, M. I.
    Halleen, J. M.
    Haapaniemi, T.
    Tanaka, A.
    Seiler, M.
    Bernoulli, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S7 - S8
  • [30] Partial Response to Zercepac® plus Chemotherapy in Triple-Positive Advanced Breast Cancer with Changed Molecular Typing
    Jiang, Fenge
    Li, Junxia
    Wang, Congcong
    Li, Ming
    Cao, Yu
    Sun, Ping
    Liu, Jiannan
    MINERVA MEDICA, 2022,
12345